Millions face deadly cholera threat in Sudan
Millions of people in Sudan are now also in urgent need of clean water and sanitation.
More than 7,700 cholera cases - including more than 1,000 cases in children under the age of five - and 185 deaths have been reported in Khartoum State since January 2025, according to UNICEF.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
10 hours ago
- News.com.au
Scott Power: ASX health stocks dip but it was a good news week for EMVision
ASX health stocks dipped 0.82% over the past five days while the broader market has risen 1.26% EMVision appoints Ramsay Health Care CEO to board and expands sites of pivotal trial First Japan site opens for Dimerix's phase III clinical trial of DMX-200 in rare kidney disease Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. Power said that, while healthcare markets were down this week, broader markets remained elevated with things starting to look more positive at the halfway mark of a thus-far volatile 2025. US President Donald Trump's trade and health policies have been impacting the sector throughout the year. At about lunchtime on Friday the S&P/ASX 200 Health Care index was down 0.82% for the past five days, while the benchmark ASX 200 rose 1.26% for the same period. "The broader market is up this week and May was a reasonably good month," he said. "We are coming up to June 30 and the end of financial year so there will be some tax-loss selling coming through across various portfolios. "June tends to be a weaker month as investors look to clean up their portfolio, while July seasonally tends to be a stronger month and there is potentially some good value out there across the smaller names which really haven't done too much for the last couple of years." Ramsay CEO joins EMVision board, trial expands EMVision Medical Devices (ASX:EMV) has had two major announcements this week including the appointment of Ramsay Health Care (ASX:RHC) CEO Carmel Monaghan as non-executive director and broadening of a pivotal trial for its emu bedside brain scanner, which is designed to rapidly diagnose stroke. Monaghan has worked across hospital, corporate and global positions at Ramsay for almost three decades. "She is highly regarded and will bring a lot of credibility and contacts into the business," Power said. He said EMvision was also making good progress with the activation of its third US site, Mount Sinai Hospital in New York, scheduled for this month. Activation of its second Australian site, Liverpool Hospital in Sydney, has also been in progress this week. Five world-leading hospitals in stroke care are now taking part in EMVision's pivotal trial with a sixth set to be activated shortly. The pivotal (validation) trial is designed to support US Food and Drug Administration (FDA) de novo (new device) clearance of the emu point-of-care brain scanner device. "The expectation is that they will get approval sometime in 2026," Power said. Power's Powerplay: Big year for Dimerix Dimerix (ASX:DXB) is Power's stock of the week after announcing it had opened the first trial site in Japan for its ACTION3 phase III drug candidate DMX-200 to treat focal segmental glomerulosclerosis (FSGS) kidney disease. Opening of Japan's first clinical trial site for ACTION3 triggers the first development milestone payment of ¥400 million (~A$4.3m) to Dimerix from FUSO Pharmaceutical Industries Ltd, its exclusive licensee of DMX-200 for FSGS in Japan. FUSO is one of four regional licensing deals executed for DMX-200, which collectively provide up to ~$1.4bn in total upfront payments and potential milestone payments, plus royalties on net sales. FSGS is a serious kidney disease that causes progressive scarring, leading to permanent damage and, ultimately, end-stage kidney failure – often requiring dialysis or a transplant. It affects adults and children and no treatments are currently approved specifically for the condition anywhere in the world, affecting overall prognosis. As a result, DMX-200 has received orphan drug designation in both the US and Europe, along with the UK's equivalent designation under the Innovative Licensing and Access Pathway (ILAP). Dimerix last year reported positive interim results from the ACTION3 trial, showing DMX-200 was performing better than placebo in reducing proteinuria with no safety concerns to date. Full enrolment in the ACTION3 study is expected by the end of 2025 with a further blinded interim analysis planned. "It's going to be a big year for Dimerix," Power said. Mayne Pharma takeover deal far from over Adelaide-headquartered pharmaceutical company Mayne Pharma (ASX:MYX) is continuing to do battle with its US-based suitor Cosette Pharmaceuticals after announcing on Wednesday it had received a notice "purporting to terminate" the $7.40 per share offer worth more than $600 million. The withdrawal comes after Cossette asserted that a "material adverse change" had occurred, and consequently freeing Cosette from its obligations under the scheme implementation deed (SID). The announcement sent the stock lower and came hours after Mayne put out another one telling the market it had not received a notice of termination, which sent its shares higher. On Thursday Mayne put out another announcement saying the scheme meeting would go ahead on June 18, as scheduled with the stock rising more than 7%. "Mayne Pharma directors continue to unanimously recommend that vote in favour of the scheme resolution at the scheme meeting, in the absence of a superior proposal," said chairman Frank Condella. However, the company needs a court decision to affirm its view that the "material adverse change" were not, in fact, material. "There is a fair bit more water to flow under the bridge with this one and it just looks very messy at the moment," Power said. ReNerve enters partnership to expand product range Biotech company ReNerve (ASX:RNV) this week announced it had entered a strategic partnership with US-based Berkeley Biologics LLC to develop and commercialise two new complementary tissue-based product ranges. The first range addresses the need for human dermal tissued, deeper layers of the skin often sourced from donors. The second product range will provide amniotic tissue products, which are known for their regenerative and healing properties. The products are set to be produced at Berkeley Biologics' California facility and launch before the end of CY25. ReNerve said the new products represent a natural extension of its existing sales activities, leveraging the same sales network and continuing to target the same surgeon and hospital customer base. The company said surgeons could incorporate additional tissue grafts when treating nerve injuries, enabling them to address both the damaged nerve and any associated trauma. "It is a strong indication that they're trying to build their sales momentum by expanding the product offering to the surgeons," Power said. "Sales are expected to grow over subsequent quarters." The views, information, or opinions expressed in the interview in th is article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.
News.com.au
10 hours ago
- News.com.au
South Australian treasurer Stephen Mullighan announces new $28m AI program in state budget
The coming AI tidal wave is beginning to hit into Australia's public sector, with the South Australian government announcing a new $28m program to embed the technological revolution into policing, healthcare, finance and law. Treasurer Stephen Mullighan delivered the surprise allocation in the state's 2025-26 budget, with the funding designed to 'maximise on the benefits and promote growing the use of AI applications across the South Australian public sector'. The budget measures claim the program will initially prioritise policing and healthcare with a set of 'proof of value trials'. 'Through targeted proof of value trials in priority areas such as health care and policing, this funding will provide support for broad applications across government and allow multiple use cases to be developed on trusted foundational technologies, with appropriate governance and alignment to the investment principles of the digital investment fund,' the document says. 'The health sector is a priority for funding consideration, as global evidence shows that integrating AI in specific areas of healthcare can reduce costs and improve operational efficiency, allowing healthcare professionals to spend more time on clinical care.' In policing, the program will look to enhance efficiency and safety for officers. 'AI can be used to support real-time decision making to help allocate resources effectively, increase officer and public safety and reduce administrative burden on officers, freeing up time for more value-added work,' the document states. 'Other areas considered for priority funding may include allied health, social work and legal and financial areas of the public sector.' The program, which sits within the government's broader digital investment fund, is funded from 2025-26 through to 2028-29, with an estimated $4.6m in yearly operating expenses and $2.4m in yearly investing expenses. Twenty full time jobs are expected to deliver the program over the period. South Australia's explicit support for AI comes as all jurisdictions grapple with the promise and peril of AI. In February this year, Queensland Information Commissioner Joanne Kummrow warned taking a 'wait and see' approach to AI risked the public sector 'falling behind understanding and responsibly engaging with its capabilities and challenges'. 'While AI shows promise as a powerful tool capable of delivering improved public services, agencies need to take the 'right path' by mitigating privacy and security risks and ensuring its ethical and transparent use, rather than taking the 'fast lane' without due regard to the necessary guard rails and protection of citizens' personal information,' she posted to the website of the Office of the Information Commissioner. The NSW government, meanwhile, funnelled more than $2.7m in grants to 16 councils in mid 2024 to trial AI in local planning systems. The trials were designed to 'improve the development application process for all users, including homeowners, councils and developers'. Outside of government, South Australia will also deploy AI to develop a fuller picture of its mineral wealth, with a particular focus on copper production in the giant Gawler Craton, which sprawls across the central portion of the state.
News.com.au
11 hours ago
- News.com.au
‘Need a pay rise': Aussies shocked by nurse's salary
A young nurse, who works up to 16 hours a day, has shocked social media users after revealing how much she gets paid. She was recently stopped on the streets of Brisbane for an interview by jobs app, Getahead, where she revealed she earns $78,000 a year working as an enrolled nurse. The worker is on the verge of finishing her registered nursing degree and plans to either continue working in her current hospital or become an army medic. During the interview, she revealed that she works between 8 to 16 hour shifts as a cardiovascular respiratory nurse, which she described as 'quite an intense job'. 'I am a carer for my grandfather. He had a heart attack a couple of years ago, [which] kind of got me into the specialty,' she said, adding that she had also cared for her grandmother when she was diagnosed with cancer. 'I just love the aspect of giving back to everyone, looking after people when they can't look after themselves is a massive thing.' When asked if she thought hospitals and the government were doing enough to 'look after' nurses, the young Aussie said she didn't think so. 'We have to fight so much for our pay increases and for our rights,' she said. 'I don't think a lot of people see how much we struggle and how emotionally exhausted we are sometimes.' The nurse said she and other people in the industry could 'definitely' do with more help and benefits. Since being shared two days ago the video has gained tens of thousands of views, with commenters sharing their shock at how much nurses really earn. 'Nurses all deserve better pay! Governments always say their nurses are valued and important but never pay them properly,' one person said. Another claimed that rate was 'too low', while another said all nurses 'need a good pay rise'. One person wrote: 'Definitely one of the most accurate interviews I've seen for nursing. Love this conversation! As a nurse I 100% agree, it's a constant battle for pay increases and for better working rights. Nurses don't get enough recognition.' According to data from the Australian Bureau of Statics, the average salary for a registered nurse in Queensland ranges from $79,058 to $106,144. An enrolled nurse salary in Queensland ranges from $71,234 to $82,599. Meanwhile, the average salary for a nurse in NSW ranges from $69,810 to $98,014. Victorian nurses have capped salaries at just below $130,000, making them among the highest paid in the country. In NSW the top classification for a registered nurse caps out at just under 100,000 in Queensland it peaks at $106,144 This is not the first time people have been left horrified after finding out how poorly some of our nurses are being paid. Earlier this year in another Getahead interview a nurse working at a private Brisbane hospital revealed that she earns around $33 an hour. 'I also work in a kitchen at the same hospital,' she added. Her admission sparked multiple stunned responses from social media users, with one person claiming there was 'no way' Australia was 'paying their nurses this low'. 'It's a joke here,' another said, with one adding: 'I make more as a barista, what?' Even though there was shock online around the woman's earnings, she claimed the 'pay' was one of the parts she loved most when it came to the job, along with 'going home to sleep'. Despite her joking response, the young worker said nurse was something she could see herself doing 'forever' and said more nurses are 'definitely needed' in Australia.
